Top-News

Teva Pharmaceutical Aktie (ADR) News

Aktie
WKN:  883035 ISIN:  US8816242098 US-Symbol:  TEVA Branche:  Pharmazeutika Land:  Israel
24,30 €
-0,1 €
-0,41%
14:27:56 Uhr
Depot/Watchlist
Marktkapitalisierung *
25,14 Mrd. €
Streubesitz
39,66%
KGV
-15,52
Dividende
0,071 €
Dividendenrendite
0,29%
Faktor
1
Originalaktie
IL0006290147
Weiter abwärts? Short handeln - Jetzt mit Hebel 26,18: VH9AAE
Werbung

Teva Pharmaceutical Aktie (ADR) News

27.05.25 - GlobeNewswire
Teva and Biolojic Design Initiate IND-enabling Studies of BD9, a Multibody Designed to Explore the Treatment of Atopic Dermatitis and Asthma
BD9 is a multibody that targets IL-13 and TSLP, and has potential to treat TH-2-driven inflammatory diseases BD9 designed using Biolojic’s Multibody Platform, which generates ...
25.05.25 - wallstreetONLINE Redaktion
Neue Favoriten: Multimilliardär Druckenmiller tauscht Nvidia, Amazon & Tesla gegen diese High-Potential-Aktien
Top-​Investor Stanley Druckenmiller kehrt Aktien wie Nvidia, Amazon, Palantir und Tesla den Rücken, während er diese aussichtsreichen Werte aufstockt.Stanley Druckenmiller ...
22.05.25 - GlobeNewswire
Teva Announces Increase of the Maximum Tender Amount of its Debt Tender Offer and Increases to Pool Tender Caps for Pool 2 Notes and Pool 3 Notes
TEL AVIV, Israel, May 22, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) (“ Teva ”) announced today that it is increasing the maximum ...
20.05.25 - GlobeNewswire
Teva Announces Successful Upsizing and Pricing of $2,300,000,000 (Equivalent) Senior Notes; Proceeds to Repay Existing Debt
TEL AVIV, Israel, May 20, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) (“ Teva ”) announced today that it successfully upsized its offering ...
20.05.25 - GlobeNewswire
Fitch Ratings Agency Upgrades Teva Rating to BB+ Recognizing Successful Execution of Its Pivot to Growth Strategy
TEL AVIV, Israel, May 20, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals (NYSE and TASE: TEVA) today announced that Fitch Ratings Agency (“Fitch”) has raised the Company's ...
19.05.25 - GlobeNewswire
Teva Announces $2,000,000,000 (Equivalent) Debt Tender Offers For Notes Due 2026-2031
TEL AVIV, Israel, May 19, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) (“ Teva ”) announced today that it has commenced tender offers ...
19.05.25 - GlobeNewswire
Teva Announces Launch of $2,000,000,000 (Equivalent) Offering of Senior Notes
TEL AVIV, Israel, May 19, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) (“ Teva ”) announced today its intention to issue $2,000,000,000 ...
16.05.25 - GlobeNewswire
Moody's Investor Services Upgrades Teva Amid Continued Success of Pivot to Growth Strategy
TEL AVIV, Israel, May 15, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals (NYSE and TASE: TEVA) today announced that Moody's Investor Services (“Moody's”) has raised the ...
12.05.25 - GlobeNewswire
Teva’s 2024 Healthy Future Report Highlights Sustainability Progress, Including Surpassed Targets Linked to Financial Strategy
The Company achieved a 29% reduction in absolute scope 1 and 2 greenhouse gas emissions from 2019 levels, surpassing its target of 25% by 2025, ahead of schedule Teva ...
07.05.25 - GlobeNewswire
Teva Reports Ninth Consecutive Quarter of Growth in Q1 2025 With Key Innovative Medicines Growing ~40%; 2025 Profit Outlook Improved
For an accessible version of this Press Release, please visit www.tevapharm.com
07.05.25 - GlobeNewswire
Teva to Host Innovation & Strategy Day on Thursday, May 29 in New York City
TEL AVIV, Israel, May 07, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that it will host Innovation & Strategy Day on ...
05.05.25 - GlobeNewswire
Teva and Alvotech Announce FDA Approval of Interchangeability for SELARSDI™ (ustekinumab-aekn) with Stelara® (ustekinumab)
The U.S. FDA has approved SELARSDI ™ ( ustekinumab-​aekn ) as interchangeable with the reference biologic Stelara ® ( ustekinumab ) in all presentations matching the reference ...
07.04.25 - GlobeNewswire
Teva and Samsung Bioepis Announce Biosimilar EPYSQLI® (eculizumab-aagh) Injection Now Available in the United States
EPYSQLI ® (eculizumab-​aagh) is now available to patients living with difficult-​to-treat rare diseases like paroxysmal nocturnal hemoglobinuria, atypical hemolytic uremic syndrome ...
07.04.25 - GlobeNewswire
Teva Announces FDA Filing Acceptance for AJOVY® (fremanezumab) in Pediatric Episodic Migraine Prevention
If approved for an expanded pediatric indication, AJOVY would be the first calcitonin gene-​related peptide (CGRP) antagonist for migraine prevention in adults and episodic migraine ...
31.03.25 - GlobeNewswire
New Data Strengthens Teva’s Schizophrenia Portfolio, Including Phase 3 SOLARIS Trial Survey Results Demonstrating Patient and Healthcare Professional Satisfaction with TEV-'749 (olanzapine) as a Once-Monthly Subcutaneous Long-Acting Injectable
More than 92% of schizophrenia patients taking TEV- ' 749 in the SOLARIS survey were satisfied or very satisfied with the initiation regimen, dosing schedule and trial medication 1 ...
27.03.25 - GlobeNewswire
Teva Releases Q1 2025 Aide Memoire
TEL AVIV, Israel, March 27, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that its Q1 2025 Aide Memoire is available ...
27.03.25 - GlobeNewswire
Teva to Host Conference Call to Discuss First Quarter 2025 Financial Results at 8 a.m. ET on May 7, 2025
TEL AVIV, Israel, March 27, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that it will issue a press release on its first ...
03.03.25 - GlobeNewswire
Teva to Present at Barclays Global Healthcare Conference and Leerink Partners Global Healthcare Conferences in March
TEL AVIV, Israel, March 03, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that Richard Francis, Teva's President and ...
27.02.25 - GlobeNewswire
2025 Community Routes: Access to Mental Health Care Grants Awarded to Clinics in Alabama, Mississippi, and Texas, Funded by Teva Pharmaceuticals
The $2 million in new funding is part of a $4 million commitment from Teva, launched in 2022, to expand access to critical mental health services across 10 states
25.02.25 - GlobeNewswire
Teva and Medincell Announce FDA Acceptance of Supplemental New Drug Application for UZEDY(R) (risperidone) Extended-Release Injectable Suspension as a Treatment for Patients with Bipolar I Disorder
UZEDY is currently approved in the US as a subcutaneous long-​acting injectable (LAI) for use every one or two months for the treatment of schizophrenia in adults 1 LAI treatment ...

Newssuche

Videos

newspaper
10:20 Uhr +1,03%
Technical Trading: Gold Zukauf Chance
Gold Long Typ: Turbo Open End WKN: VC5S7W Hebel: 2 Laufzeit: OpenEnd Einstieg: Market ... Mehr »